



FORM PTO - 1449

ATTORNEY DOCKET NO.: LEX-002C1 (4006/13)

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

APPLICANT(S): Gillies et al.

SERIAL NO.: 10/005,212

FILING DATE: December 4, 2001 GROUP: 1646

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
PM	A51	5,019,368	5/28/91	Epstein et al.			
	A52	5,538,866	7/23/96	Israeli et al.			
	A53	5,645,835	7/8/97	Fell, Jr. et al.			
	A54	5,709,859	1/20/98	Aruffo et al.			
	A55	5,807,715	9/15/98	Morrison et al.			
	A56	5,922,685	7/13/99	Rakhmilevich et al.			
	A57	6,277,375 B1	8/21/01	Ward			
	A58	6,348,192	2/19/02	Chan et al.			
	A59	6,406,689 B1	6/18/02	Falkenberg et al.			

RECEIVED  
JUL 21 2003  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
PM	B82	0 318 554	6/7/89	EP					Y
	B83	WO 95/31483	11/23/95	PCT					Y
	B84	WO 99/60128	11/25/99	PCT					Y
	B85	WO 00/78334	12/28/00	PCT					Y
	B86	WO 01/10912	2/15/01	PCT					Y
	B87	WO 03/015697	2/27/03	PCT					Y

EXAM. INIT. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

PM	C140	Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237.
	C141	Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci.</u> , 93:7826-7831.
	C142	Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," <u>Ann. Rev. Biochem.</u> , 57:505-518.
	C143	Bissery et al., (1997), <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher Edition, Ch. 8.
	C144	Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307:2:411-415.

EXAMINER *Prerna Menz*

DATE CONSIDERED 11/17/03



FORM PTO - 1449

ATTORNEY DOCKET NO.: LEX-002C1 (4006/13)

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

APPLICANT(S): Gillies et al.

SERIAL NO.: 10/005,212

FILING DATE: December 4, 2001 GROUP: 1648

TECH CENTER 1600/2900  
JUL 21 2003  
RECEIVED

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
PM	C145	Caton et al., (1986), "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin," <u>The EMBO Journal</u> , 5:7:1577-1587.
	C146	Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271:23:13349-13355.
	C147	Chuang et al., (1993), "Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes," <u>Gynecol. Oncol.</u> , 49:291-298.
	C148	Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci.</u> , 85:7709-7713.
	C149	Fell et al., (1992), "Chimeric L6 antitumor antibody," <u>The J. of Biol. Chem.</u> , 267:22:15552-15558.
	C150	Griffon-Etienne et al., (1999), "Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications," <u>Cancer Research</u> , 59:3776-3782.
	C151	Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human FcγRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , 97:2:331-338.
	C152	Hornick et al., (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," <u>Clin. Cancer Res.</u> , 5:51-60.
	C153	Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004.
	C154	Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2," <u>Journal of Biological Chemistry</u> , 262:12:5723-5731.
	C155	Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , 92:3730-3736.
	C156	Lode et al., (1998), "Immunocytokines: a promising approach to cancer immunotherapy," <u>Pharmacol. Thera.</u> , 80:277-292.
	C157	Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> , 247:979-994.
	C158	Mullins et al., (1998), "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20:473-492.
	C159	Netti et al., (1995), "Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery," <u>Cancer Research</u> , 55:5451-5458.
	C160	Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," <u>Proc. Nat. Acad. Sci.</u> , 96:3137-3142.
	C161	Polizzi et al., (1999), "A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts," <u>Cancer Res.</u> , 59:1036-1040.
	C162	Roessler et al., (1994), "Cooperative Interactions between the interleukin 2 receptor α and β chains alter the interleukin 2-binding affinity of the receptor subunits," <u>Proc. Natl. Acad. Sci.</u> , 91:3344-3347.
EXAMINER	Berna Mendi	
	DATE CONSIDERED 11/17/03	

RECEIVED  
JUL 21 2003  
TECH CENTER 1600/2900

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-002C1 (4006/15)	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 10/005,212	
		FILING DATE: December 4, 2001      GROUP: 1646	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
pm	C163	Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , Third Edition, 8.3-8.4.	
	C164	Sauve et al., (1991), "Localization in human interleukin 2 of the binding site of the $\alpha$ chain (p55) of the interleukin 2 receptor," <u>Proc. Natl. Acad. Sci.</u> , 88:4636-4640.	
	C165	Shanafelt et al., (2000), "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo," <u>Nature Biotechnology</u> , 18:1197-1202.	
	C166	Sharma et al., (1999), "T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function," <u>J. Immunol.</u> , 163:5020-5028.	
	C167	Sulitzeanu et al., (1993), "Immunosuppressive factors in human cancer," <u>Adv. Cancer Res.</u> , 60:247-267.	
	C168	Villunger et al., (1997), "Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance," <u>Blood</u> , 90:12-20.	
	C169	Watanabe et al., (1997), "Long-term depletion of naive T cells in patients treated for Hodgkin's disease," <u>Blood</u> , 90:3662-3672.	
EXAMINER	Prerna Menz		DATE CONSIDERED 11/17/03

FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-0550  
RECEIVED  
TECH CENTER 1800/2900

APPLICANT(S): Gillies et al.

03 MAR 10 AM 9:05

SERIAL NO.: 10/005,212

FILING DATE: December 4, 2001

GROUP: 1646

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
PM	A1	07/348,237	5/5/89	Rosenblum et al.			
	A2	4,196,265	4/1/80	Koprowski et al.			
	A3	4,469,797	9/4/84	Albarella			
	A4	4,676,980	6/30/87	Segal et al.			
	A5	4,816,567	3/28/89	Cabilly et al.			
	A6	4,946,778	8/7/90	Ladner et al.			
	A7	5,073,627	12/17/91	Curtis et al.			
	A8	5,114,711	5/19/92	Bell et al.			
	A9	5,116,964	5/26/92	Capon et al.			
	A10	5,199,942	4/6/93	Gillis			
	A11	5,225,538	7/6/93	Capon et al.			
	A12	5,225,539	7/6/93	Winter			
	A13	5,258,498	11/2/93	Huston et al.			
	A14	5,314,995	5/24/94	Fell, Jr. et al.			
	A15	5,349,053	9/20/94	Landolfi			
	A16	5,514,582	5/7/96	Capon et al.			
	A17	5,541,087	7/30/96	Lo et al.			
	A18	5,543,297	8/6/96	Cromlish, et al.			
	A19	5,552,524	09/03/96	Basinski et al.			
	A20	5,585,089	12/17/96	Queen et al.			
	A21	5,609,846	3/11/97	Goldenberg			
	A22	5,639,725	6/17/97	O'Reilly et al.			
	A23	5,650,150	7/22/97	Gillies			
	A24	5,650,492	7/22/97	Gately, et al.			
	A25	5,667,776	9/16/97	Zimmerman et al.			

EXAMINER

Penna Mung

DATE CONSIDERED

6/30/03

<b>FORM PTO - 1449</b>				<b>ATTORNEY DOCKET NO.: LEX-002C1</b>			
<b>INFORMATION DISCLOSURE STATEMENT</b>				<b>APPLICANT(S): Gillies et al.</b>			
				<b>SERIAL NO.: 10/005,212</b>			
				<b>FILING DATE: December 4, 2001</b>		<b>GROUP: 1646</b>	
<b>U.S. PATENT DOCUMENTS</b>							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<i>Pm</i>	A26	5,691,309	11/25/97	Basinski et al.			
	A27	5,719,266	02/17/98	DiMarchi et al.			
	A28	5,723,125	3/3/98	Chang et al.			
	A29	5,726,044	3/10/98	Lo et al.			
	A30	5,728,552	3/17/98	Fujisawa et al.			
	A31	5,733,876	3/31/98	O'Reilly et al.			
	A32	5,756,461	05/26/98	Stephens			
	A33	5,759,551	6/2/98	Ladd et al.			
	A34	5,770,195	6/23/98	Hudziak et al.			
	A35	5,800,810	9/1/98	Doyle et al.			
	A36	5,827,516	10/27/98	Urban et al.			
	A37	5,837,682	11/17/98	Folkman et al.			
	A38	5,843,423	12/1/98	Lyman et al.			
	A39	5,854,205	12/29/98	O'Reilly et al.			
	A40	5,858,347	1/12/99	Bauer et al.			
	A41	5,885,795	3/23/99	O'Reilly et al.			
	A42	5,886,178	3/23/99	Allen et al.			
	A43	5,908,626	6/1/99	Chang et al.			
	A44	5,994,126	11/30/99	Steinman et al.			
	A45	6,080,409	6/27/00	Laus et al.			
	A46	6,086,875	7/11/00	Blumberg et al.			
	A47	6,100,387	8/8/00	Herrmann et al.			
	A48	6,169,070	1/2/01	Chen et al.			
	A49	6,171,588	1/9/01	Carron et al.			
	A50	5,359,035	10/25/94	Habermann			
<b>EXAMINER</b> <i>Prerna Menz</i>				<b>DATE CONSIDERED</b> <i>6/30/03</i>			

FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-002C1

APPLICANT(S): Gillies et al.

SERIAL NO.: 10/005,212

FILING DATE: December 4, 2001

GROUP: 1646

## FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILIN G DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
PM	B1	0 158 198	10/16/85	EP					Y
	B2	0 211 769	2/25/87	EP					Y
	B3	0 256 714	2/24/88	EP					Y
	B4	0 294 703	12/14/88	EP					Y
	B5	0 308 936	3/29/89	EP					Y
	B6	0 314 317	5/3/89	EP					Y
	B7	0 319 012	6/7/89	EP					Y
	B8	0 326 120	4/15/98	EP					Y
	B9	0 350 230	1/10/90	EP					Y
	B10	0 375 562	6/27/90	EP					Y
	B11	0 396 387	11/7/90	EP					Y
	B12	0 439 095	7/31/91	EP					Y
	B13	0 511 747	11/4/92	EP					Y
	B14	0 601 043	11/25/98	EP					Y
	B15	0 706 799	4/17/96	EP					Y
	B16	0 790 309	8/20/97	EP					Y
	B17	21725/88	3/23/89	AU					Y
	B18	93100115.3	7/14/93	CN				B77 is English abstract	N
	B19	37 12985	11/3/88	DE				B78 is English abstract; A50 is English counterpart	N
	B20	2 292 382	2/21/96	GB					Y
	B21	63-267278	11/4/88	JP				B79 is English abstract	N
	B22	63-267296	11/4/88	JP				B80 is English abstract; B81 is English counter part	N
	B23	WO 86/01533	3/13/86	PCT					Y
↓	B24	WO 88/00052	1/14/88	PCT					Y

EXAMINER

Penna Muntz

DATE CONSIDERED

6/30/03

FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-002C1

APPLICANT(S): Gillies et al.

SERIAL NO.: 10/005,212

FILING DATE: December 4, 2001

GROUP: 1646

## FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILIN G DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
PM	B25	WO 88/09344	12/1/88	PCT					Y
	B26	WO 89/02922	4/6/89	PCT					Y
	B27	WO 89/09620	10/19/89	PCT				Abstract in English	N
	B28	WO 90/03801	4/19/90	PCT					Y
	B29	WO 91/00360	1/10/91	PCT					Y
	B30	WO 91/04329	04/04/91	PCT					Y
	B31	WO 91/08298	6/13/91	PCT					Y
	B32	WO 91/13166	9/5/91	PCT					Y
	B33	WO 91/14438	10/3/91	PCT					Y
	B34	WO 92/02240	2/20/92	PCT					Y
	B35	WO 92/08495	5/29/92	PCT					Y
	B36	WO 92/08801	5/29/92	PCT					Y
	B37	WO 92/16562	10/1/92	PCT					Y
	B38	WO 93/03157	2/18/93	PCT					Y
	B39	WO 93/10229	5/27/93	PCT					Y
	B40	WO 95/05468	2/23/95	PCT					Y
	B41	WO 95/21258	8/10/95	PCT					Y
	B42	WO 95/28427	10/26/95	PCT					Y
	B43	WO 96/04388	02/15/96	PCT					Y
	B44	WO 96/05309	2/22/96	PCT					Y
	B45	WO 96/08570	3/21/96	PCT					Y
	B46	WO 96/18412	6/20/96	PCT					Y
	B47	WO 96/31526	10/10/96	PCT					Y
	B48	WO 97/00317	9/18/97	PCT					Y
✓	B49	WO 97/00319	1/3/97	PCT					Y

EXAMINER

Prerna Menz

DATE CONSIDERED

6/21/03

<b>FORM PTO - 1449</b>					<b>ATTORNEY DOCKET NO.: LEX-002C1</b>				
<b>INFORMATION DISCLOSURE STATEMENT</b>					<b>APPLICANT(S): Gillies et al.</b>				
					<b>SERIAL NO.: 10/005,212</b>				
					<b>FILING DATE: December 4, 2001</b>		<b>GROUP: 1646</b>		
<b>FOREIGN PATENT DOCUMENTS</b>									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
PM	B50	WO 97/15666	5/1/97	PCT					Y
	B51	WO 97/20062	6/5/97	PCT					Y
	B52	WO 97/24137	7/10/97	PCT					Y
	B53	WO 97/24440	7/10/97	PCT					Y
	B54	WO 97/26335	7/24/97	PCT					Y
	B55	WO 97/30089	8/21/97	PCT					Y
	B56	WO 97/33617	9/18/97	PCT					Y
	B57	WO 97/33619	1/3/97	PCT					Y
	B58	WO 97/34631	9/25/97	PCT					Y
	B59	WO 98/00127	1/8/98	PCT					Y
	B60	WO 98/06752	2/19/98	PCT					Y
	B61	WO 98/28427	7/2/98	PCT					Y
	B62	WO 98/30706	7/16/98	PCT					Y
	B63	WO 98/46257	10/98	PCT					Y
	B64	WO 98/59244	12/30/98	PCT					Y
	B65	WO 99/02709	01/21/99	PCT					Y
	B66	WO 99/03887	01/28/99	PCT					Y
	B67	WO 99/29732	6/17/99	PCT					Y
	B68	WO 99/43713	9/2/99	PCT					Y
	B69	WO 99/52562	10/21/99	PCT					Y
	B70	WO 99/53958	10/28/99	PCT					Y
	B71	WO 99/62944	12/09/99	PCT					Y
	B72	WO 00/11033	3/2/00	PCT					Y
	B73	WO 00/34317	06/15/00	PCT					Y
↓	B74	WO 00/40615	7/13/00	PCT					Y
<b>EXAMINER</b> <i>Prima Mung</i>					<b>DATE CONSIDERED</b> <i>6/22/03</i>				



FORM PTO - 1449					ATTORNEY DOCKET NO.: LEX-002C1				
INFORMATION DISCLOSURE STATEMENT					APPLICANT(S): Gillies et al.				
					SERIAL NO.: 10/005,212				
					FILING DATE: December 4, 2001		GROUP: 1646		
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
PM	B75	WO 00/69913	11/23/02	PCT					Y
	B76	WO 01/07081	2/1/01	PCT					Y
	B77	93100115.3	7/14/93	CN				English abstract of B18	Y
	B78	37 12985	11/3/88	DE				English abstract of B19	Y
	B79	63-267278	11/4/88	JP				English abstract of B21	Y
	B80	63-267296	11/4/88	JP				English abstract of B22	Y
	B81	0 237 019	9/16/87	EP				English counterpart of B22	Y
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
PM	C1	Abaza et al., (1992) "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization" <u>Journal of Protein Chemistry</u> , Vol. 11, No. 5: pp. 433-444.							
	C2	Abstract XP-002116766, (1996) "Prostaglandins, their inhibitors and cancer" <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , Vol. 54, No. 2, pp. 83-94.							
	C3	Arenberg et al. (1996) "Interferon- $\gamma$ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , Vol. 184, pp. 981-992.							
	C4	Bacha et al., (1988). "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein", <u>J. Experimental Medicine</u> , Vol. 167, pp. 612-622							
	C5	Bachelot et al., (March 1998) "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo", <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , Vol. 39, pp. 271, Abstract #1856.							
	C6	Barnett et al. (1994) "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," <u>Biochimica et Biophysica Acta</u> , 1209:130-139.							
	C7	Baselga, et al (1998) "Recombinant Humanized Anti-HER2 Antibody (Herceptin <sup>TM</sup> ) Enhances the Antitumor activity of Paclitaxel and Doxorubicin against HER3/neu Overexpressing Human Breast Cancer Xenografts." <u>Cancer Research</u> , Vol. 58, pp. 2825-2831.							
EXAMINER <i>Prerna Mehta</i>					DATE CONSIDERED <i>6/30/03</i>				

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-002C1	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 10/005,212	
		FILING DATE: December 4, 2001      GROUP: 1646	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
pm	C8	Batova et al., (1999), "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , Vol. 5, No. 12, pp. 4259-4263.	
	C9	Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, pp. 2702-2707.	
	C10	Beutler et al., (1988) "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator", <u>Ann. Rev. Biochem.</u> , Vol. 57, pp. 505-518.	
	C11	Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins" <u>Cancer Research</u> , Vol. 45, pp. 1214-1221.	
	C12	Boehm et al. (1997) "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," <u>Letters to Nature</u> , Vol. 390, pp. 404-407.	
	C13	Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , Vol. 252, pp. 190-194.	
	C14	Brooks et al. (1994), "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , Vol. 79, pp. 1157-1164.	
	C15	Burgess et al., (1990), "Possible Dissociation of the heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , Vol. 111, pp. 2129-2138.	
	C16	Canfield et al. (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>Journal of Experimental Medicine</u> , Vol. 173, No. 6, pp. 1483-1491.	
	C17	Cao et al., (1996), "Kringles of Human Angiostatin," <u>The Journal of Biological Chemistry</u> , Vol. 271, No. 46, pp. 29461-29467.	
	C18	Cao et al. (1997), "Kringles of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , Vol. 272, No. 36, pp. 22924-22928.	
	C19	Capon et al. (1989), "Designing CD4 immunoadhesins for AIDS therapy," <u>Nature</u> , Vol. 337, pp. 525-531.	
	C20	Chan et al., (1991) "Induction of Interferon $\gamma$ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , pp. 869-879.	
	C21	Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , Vol. 5, pp. 385-90.	
	C22	Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin" <u>Nature</u> , Vol. 339, pp. 394-397.	
EXAMINER	Penna Mendi		DATE CONSIDERED 6/20/03

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-002C1	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 10/005,212	
		FILING DATE: December 4, 2001      GROUP: 1646	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
PM	C23	Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," <u>Nature</u> , Vol. 335, pp. 370-372.	
	C24	Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , Vol. 159, No. 1, pp. 351-358.	
	C25	Cheon et al. (1994) "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," <u>Proc. Natl. Acad. Sci. USA</u> 91: 989-993.	
	C26	Cohen, S. L. et al., (August 15, 1996), "Human leptin characterization," <u>Nature</u> , Vol. 382, p. 589.	
	C27	Cole et al. (1997) "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , Vol. 159, pp. 3613-3621.	
	C28	Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , Vol. 56, pp. 2531-2534.	
	C29	D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 91, pp. 4082-4085.	
	C30	D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , Vol. 176, pp. 1387-1398.	
	C31	Ding et al., (September 1988), "Zinc-Dependent Dimers Observed in Crystals of Human Edostatin," <u>Proceedings of the National Academy of Sciences of USA</u> , Vol. 95, No. 18, pp. 10443-10448.	
	C32	Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem. Supp.</u> , Vol. 161, pp. 156-166.	
	C33	Eisenthal, (1990) "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," <u>Cancer Immunol. Immunotherap.</u> Vol. 31, pp. 342-348.	
	C34	Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>The J. of Immunology</u> , Vol. 146, pp. 2446-2452.	
	C35	Friedman, J. M. et al., (October 22, 1998). "Leptin and the regulation of body weight in mammals," <u>Nature</u> , Vol. 395, pp. 763-770.	
	C36	Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," <u>Science</u> , Vol. 226, pp. 1339-134.	
	C37	Gately et al., (1998), "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses" <u>Annu. Rev. Immunol.</u> , Vol. 16, pp. 495-521.	
↓	C38	Gillessen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist" <u>Eur. J. Immunol.</u> , Vol. 25, pp. 200-206.	
EXAMINER	Panna Menti		DATE CONSIDERED 6/30/03

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-002C1	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 10/005,212	
		FILING DATE: December 4, 2001      GROUP: 1646	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
PM	C39	Gillies et al. (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <u>Hum. Antibod. Hybridomas</u> Vol. 1, No. 1, pp. 47-54.	
	C40	Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , Vol. 125, pp. 191-202.	
	C41	Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Science</u> , Vol. 89, pp. 1428-1432.	
	C42	Gillies et al., (1993), "Biological Activity and In Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , Vol. 4, pp. 230-235.	
	C43	Gillies, et al., (June 1998), "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases," <u>Journal Immunology</u> , Vol. 160, No. 12, pp. 6195-6203.	
	C44	Gillies, et al., (1999 May), "Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors," <u>Cancer Research</u> , Vol. 59, No. 9, pp 2159-2166.	
	C45	Gillies et al., (1989), "Expression of Human Anti-Tetanus toxoid antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , Vol. 7, pp. 799-804.	
	C46	Gillies et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>Journal of Immunology</u> , Vol. 120, No. 6, pp. 2027-2032.	
	C47	Goeddel et al., (1986), "Tumor Necrosis Factors; Gene Structure and Biological Activities," <u>Pharm. Sciences</u> , pp. 597-609.	
	C48	Gren et al., (1983), "A New Type of Leukocytic Interferon," <u>Dokl. Biochem.</u> , Vol. 269, pp. 91-95.	
	C49	Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , Vol. 73, No. 8, pp. 2081-2805.	
	C50	Guyre et al., (1997), "Increased potency of Fc-receptor-targeted antigens," <u>Cancer Immunol. Immunother.</u> Vol. 45, pp. 146-148.	
	C51	Harris et al., "Therapeutic Antibodies - the Coming of Age" <u>Tibtech</u> , 11:42-44 (Feb. 1993).	
	C52	Harvill et al. (1996 October), "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation." <u>Journal of Immunology</u> , Vol. 157, No. 7, pp. 3165-3170.	
	C53	Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , Vol. 11, Issue 6, pp. 629-636.	
	C54	He et al. (1998) "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E- and P-Selectin," <u>J. Immunol.</u> 1029-1035.	
↓	C55	Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers" <u>In Vivo Biology of IL-12 p40 Homodimer</u> , <u>Journal of Immunology</u> , Vol. 158, pp. 4381-4388.	
EXAMINER	Penna Muntz		DATE CONSIDERED 6/30/03

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-002C1	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 10/005,212	
		FILING DATE: December 4, 2001      GROUP: 1646	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
Pm	C56	Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 83, No. 18, pp. 7059-7063.	
	C57	Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , Vol. 3, pp. 31-58.	
	C58	Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , Vol. 7, No. 2, pp. 159-167.	
	C59	Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1/5 Å Resolution," <u>EMBO Journal</u> , Vol. 17, No. 6, pp. 1656-1664.	
	C60	Holden, et al. (2001) "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents." <u>Proceedings of the American Association for Cancer Research</u> , Vol. 42, p. 683.	
	C61	Holden, et al. (2001) "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents" <u>Clinical Cancer Research</u> ; Vol. 7, No. 9, pp. 2862-2869.	
	C62	Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , Vol. 1096, No. 4, pp. :345-354 (Abstract).	
	C63	Hoogenboom et al., (1991), "Constriction and expression of antibody-tumor necrosis factor fusion proteins," <u>Molecular Immunology</u> , Vol. 28, No. 9, pp. 1027-1037	
	C64	Huck et al. (1986) "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human C <sub>γ</sub> genes," <u>Nucleic Acids Research</u> , Vol. 14, No. 4, pp. 1779-1789.	
	C65	Huse et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , Vol. 246, pp. 1275-1281.	
	C66	Ingber et al. (1990) "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," <u>Nature</u> , Vol. 348, pp. 555-557.	
	C67	Jones et al., (1986) "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <u>Nature</u> , Vol. 321, No. 6069, pp. 522-525.	
	C68	Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 83, pp. 4479-4483.	
	C69	Junghans et al. (1996) "The protection receptor of IgG catabolism is the B2-microglobulin-containing neonatal intestinal transport receptor," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, No. 11, pp. 5512-5516.	
✓	C70	Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 88, pp. 11120-11123.	
EXAMINER		DATE CONSIDERED	
Prema Menz		6/30/03	

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-002C1	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 10/005,212	
		FILING DATE: December 4, 2001      GROUP: 1646	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
PM	C71	Kappel, et al. (1992) "Regulating gene expression in transgenic animals," Current Opinion in Biotechnology 3:548-553	
	C72	Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFc $\lambda$ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , Vol. 160, No. 6, pp. 1686-1701.	
	C73	Kendra et al., (1999), "Pharmacokinetics and stability of the ch 14.18-interleukin-2 fusion protein in mice," <u>Cancer Immunol. Immunotherapy</u> , Vol. 48, pp. 219-229.	
	C74	Kim, et al. (1999) "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV" <u>Journal of Interferon and Cytokine Research</u> , Vol. 19, pp. 77-84.	
	C75	Kim, et al., (May 1997), "An Ovalbumin-IL-12 fusion protein is more effective than oval bumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production." <u>Journal Immunology</u> , Vol. 158, No. 9, pp. 4137-4144.	
	C76	Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 81, 7922-7926.	
	C77	Kuo, et al. (2001) "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," <u>Journal of Cell Biology</u> , Vol. 152, No. 6, pp. 1233-1246.	
	C78	LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , Vol. 268, No. 31, pp. 23311-23317.	
	C79	Lazar et al., (1988), "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> Vol. 8, No. 3, pp. 1247-1252.	
	C80	LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , Vol. 51, pp. 2694-2698.	
	C81	Lieschke, et al., (January 1997), "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo." <u>Nature Biotechnology</u> , Vol. 15, No. 1, pp. 35-40.	
	C82	Linsley et al. (1991) "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>Journal of Experimental Medicine</u> , Vol. 174, No. 3, pp. 561-569.	
	C83	Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , Vol. 239, pp. 395-398.	
	C84	Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 82, pp. 8648-8652.	
	C85	Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells" <u>Protein Engineering</u> , Vol. 11, No. 6, pp. 495-500.	
↓	C86	Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , Vol. 91, No. 5, pp. 1706-1715.	
EXAMINER		DATE CONSIDERED	
Penna Mandy		6/30/03	

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-002C1	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 10/005,212	
		FILING DATE: December 4, 2001      GROUP: 1646	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
Pm	C87	Lode et al., (1999), "Synergy between an antiangiogenic integrin $\alpha_v$ antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 1591-1596.	
	C88	Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , Vol. 29, No. 2, pp. 117-120.	
	C89	Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 8591-8596.	
	C90	Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , Vol. 84, No. 8, pp. 2457-2466.	
	C91	Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> Vol. 25, pp. 137-146.	
	C92	Mark et al., (December 1992), "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins," <u>Journal of Biological Chemistry</u> , Vol. 267, No. 36, pp. 26166-26171.	
	C93	Medesan et al. (1997) "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1 <sup>1</sup> ," <u>Journal Immunology</u> , Vol. 158, No. 5, pp. 2211-2217.	
	C94	Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , Vol. 57, pp. 2890-2895.	
	C95	Mosmann et al., (1989), "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> Vol. 7, pp. 145-173.	
	C96	Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related $\alpha$ -melanocyte-stimulating hormone fusion protein," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 83, pp. 8258-8262.	
	C97	Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach to chimeric toxin development," <u>Immunotoxins</u> , pp. 123-140.	
	C98	Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , Vol. 13, No. 17, pp. 6361-6373.	
	C99	Neuberger, et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions.," <u>Nature</u> , Vol. 312, pp. 604-608.	
	C100	O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , Vol. 79, pp. 315-328.	
	C101	O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," <u>Nature Medicine</u> , Vol. 2, No. 6, pp. 689-692.	
	C102	O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , Vol. 88 pp. 277-285.	
EXAMINER	Penna mung		DATE CONSIDERED 6/30/03

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-002C1	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 10/005,212	
		FILING DATE: December 4, 2001      GROUP: 1646	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
PM	C103	Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins", <u>Journal of Biological Chemistry</u> , Vol. 264, No. 26, pp. 15157-15160.	
	C104	Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , Vol. 6, pp. 407-438.	
	C105	Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," <u>J. Exp. Medicine</u> , Vol. 163, pp. 166-178.	
	C106	Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>Journal Immunology</u> , Vol. 142, No. 10, pp. 3662-3667.	
	C107	Putzer et al. (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Nat'l Acad. Sci.</u> , Vol. 94, pp. 10889-10894.	
	C108	Reisfeld et al., (1996), "Recombinant antibody fusion proteins for cancer immunotherapy," <u>Current Topics in Microbiology and Immunology</u> , pp. 27-53.	
	C109	Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," <u>Melanoma Research</u> , Vol. 7, Suppl. 2, pp. S99-S106.	
	C110	Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <u>The Lancet</u> , Vol. 343, pp. 1177-1183.	
	C111	Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," <u>Immunology Today</u> , Vol. 9, No. 2, pp. 58-62.	
	C112	Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," <u>Structure</u> 2, Vol. 2, No. 3, pp. 159-173.	
	C113	Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , Vol. 46, pp. 4701-4705.	
	C114	Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," <u>The EMBO Journal</u> , Vol. 17, No. 15, pp. 4249-4256.	
	C115	Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminogen activator," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 84, pp. 6904-6908.	
	C116	Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>Journal of Immunology</u> , Vol. 148, No. 11, pp. 3433-3340.	
	C117	Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," <u>Proc. Natl. Acad. Sci USA</u> , Vol. 85, No. 13, pp. 4842-4846.	
	C118	Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG mediates cytotoxicity by Human Monocytes that is enhanced by interferon-λ and is not blocked by human IgG," <u>Journal of Immunology</u> , Vol. 137, No. 11, pp. 3378-3382.	
EXAMINER	Penna Menly		DATE CONSIDERED 6/30/03



FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-002C1	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 10/005,212	
		FILING DATE: December 4, 2001      GROUP: 1646	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
PM	C119	Shiff et al., (1995), "Sulindac Sulfide, an Aspirin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , Vol. 96, pp. 491-503.	
	C120	Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor I: Potential applications for cellular targeting," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 87, pp. 5322-5326.	
	C121	Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , Vol. 57, pp. 1329-1334.	
	C122	Stevenson et al., (1997), "Conjugation of Human Fcγ in Closed-Hinge or Open-Hinge Configuration to Fab'y and Analogous Ligands," <u>Journal of Immunology</u> , Vol. 158, pp. 2242-2250.	
	C123	Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," <u>Nature</u> , Vol. 302, pp. 305-309.	
	C124	Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>Journal of Immunology</u> , Vol. 143, No. 8, pp. 2595-2601.	
	C125	Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>Journal of Experimental Medicine</u> , Vol. 178, No. 2, pp. 661-667.	
	C126	Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , Vol. 57, pp. 920-925.	
	C127	<u>The Merck Manual of Diagnosis and Therapy</u> , 990-993, 1278-1283 (17 <sup>th</sup> ed. 1999).	
	C128	Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , Vol. 48, No. 5, pp. 1119-1123	
	C129	Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , Vol. 242, pp. 1166-1168	
	C130	Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , Vol. 84, pp. 4008-4027.	
	C131	Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , Vol. 56, pp. 467-470.	
	C132	Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," <u>Cancer Research</u> , Vol. 44, pp. 681-687.	
	C133	Verhoeven et al. (1988) "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> 239:1534-1536.	
EXAMINER	Prema Manf		DATE CONSIDERED 6/20/03

<b>FORM PTO - 1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTORNEY DOCKET NO.: LEX-002C1  APPLICANT(S): Gillies et al.  SERIAL NO.: 10/005,212  FILING DATE: December 4, 2001      GROUP: 1646	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
pm	C134	Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein", <u>Protein Engineering</u> , Vol. 1, No. 6, pp. 493-498.	
	C135	Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment," <u>Gene</u> , Vol. 43, pp. 319-324.	
	C136	Wooley et al. (1993) "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice," J. Immunol. 151: 6602-6607.	
	C137	Wu et al., (July 1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin", <u>Biochemical and Biophysical Research Communications</u> , Vol. 236, No. 3, pp. 651-654.	
	C138	Xiang et al. (1997) "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , Vol. 57, pp. 4948-4955.	
	C139	Xin Xau Zheng, et al., (1995 ), "Administration of nonstolytic IL-10/Fc in muring models of lipopolysaccaride-induced septic shock and allogenic islet transplantation." <u>Journal Immunology</u> , Vol. 154, No. 10, pp 5590-5600.	
EXAMINER	Prerna Menz		DATE CONSIDERED 6/30/03

2578831